Sapient

We're ready for Day 1 of #BiomarkersUS! Stop by Sapient's Booth 13 to meet our team including Sean Ramsey, KJ Banuk, Mo Jain, MD PhD, and Jonathan Usuka. Also don't miss Dr. Jain's scientific session at 12:00pm, where he will discuss how #biopharma companies are leveraging #multiomics data from early target identification through to clinical studies. (Track 2 meeting room) See you here! #BiomarkersOG Oxford Global

🚀 **Sapient partners with Rancho BioSciences to accelerate the next generation of its Human Biology Database** 🚀 Sapient is excited to announce its collaboration with Rancho BioSciences to expand and accelerate the development of our **Human Biology Database**. This next-gen infrastructure will enable rapid ingestion and homogenization of multi-omics and real-world data, allowing us to deliver even more robust insights for our clients in biomarker discovery and drug development. *“We believe strongly that integrated multi-omics data will play a critical role in the future of drug development, revealing how varied molecular interactions influence disease,”* said Tao Long, Co-Founder and Head of Data Science at Sapient. *“This partnership with Rancho BioSciences will create a pathway to efficiently add more types of omics data and increase the speed, versatility, and depth of our analyses.”* We are thrilled to work with Rancho BioSciences and leverage their expertise in life science data curation to support the future of data-driven insights for precision medicine. #BiomarkerDiscovery #MultiOmics #DataScience #DrugDevelopment #RealWorldData #LifeSciences #Sapient #RanchoBioSciences #PrecisionMedicine #OmicsData

We are excited to share that we've partnered with Rancho BioSciences to accelerate the next generation of our Human Biology Database. Rancho will support a data infrastructure expansion to both accelerate the ingestion of additional #multiomics and real-world data and to homogenize this new data with the rich datasets that already exist. See how the collaboration will help to increase the breadth and depth of multidimensional insights we can deliver to inform #drugdevelopment. https://lnkd.in/gpyNWnUe

October is #BreastCancerAwarenessMonth 🎗️ We 𝐆𝐎 𝐏𝐈𝐍𝐊 🎗️ today to show our support for patients and families affected by this disease, as well as to raise awareness around the promising advancements occurring in breast cancer research today. The #SapientTeam is proud to support the hard work our clients are doing to treat and defeat cancer, and see firsthand how innovative new drugs are improving treatments and the lives of breast cancer patients. While we 𝐆𝐎 𝐏𝐈𝐍𝐊 🎗️ for one day, we're committed every day to helping bring transformative cancer therapies to market most efficiently. And to help bring hope to women currently undergoing treatment, our employees organized a donation drive with #Chemoccessories – a nonprofit that provides breast cancer patients with scarves and hats to lift their spirits, boost their confidence, and feel more like themselves during a difficult time. If you're interested in supporting Chemoccessories' great efforts, you can check out all the accessories they accept as donations here: https://lnkd.in/gvnisy-Q

Will you be attending #BiomarkersUS next week? See all the ways you can meet up with Sapient's team – including Mo Jain, MD PhD, Sean Ramsey, and KJ Banuk – during the conference: https://lnkd.in/gZWCwiW8 Be sure to stop by Booth #13 to see us and learn how we can accelerate your #drugdevelopment efforts with rapid discovery of #dynamicbiomarkers (+ grab some fun swag 🧦✨). You can also join our talk entitled "From target ID through clinical studies: leveraging multi-omics data to accelerate drug discovery and development" – details here: https://lnkd.in/dUNUHJzU Pre-schedule a time to talk on site here: https://lnkd.in/g3CHKnWs Oxford Global #BiomarkersSeries #BiomarkersOG

This timely review in Nature Portfolio Metabolic Health and Disease provides an overview of the translational potential of #metabolic and #lipidomic biomarkers for predicting breast cancer prognosis and response to therapy. https://lnkd.in/gmRbh4ca Despite significant advancements in treatments, most breast cancer-related deaths result from metastasis for which there is no treatment. The paper highlights the potential of dynamic small molecule biomarkers to enable early detection of #breastcancer before it spreads, as well as to facilitate development of personalized treatment plans based on the molecular profile of each tumor. This can improve therapeutic outcomes and help avoid overtreatment and the associated side effects, improving quality of life for patients. Read the full review to learn more about the opportunities and outlook for these omics techniques in breast cancer trials: https://lnkd.in/gmRbh4ca #BreastCancerAwarenessMonth

We're #hiring a new Business Development / Sr. Business Development Director in United States. Apply today or share this post with your network.

Dysregulated #bioactivelipid levels have been reported in diseases ranging from cancer to diabetes to cardiovascular disease. See how Sapient's semi-targeted LC-MS/MS method, optimized specifically for analysis and discovery of bioactive #metabolites, enables rapid profiling of a broad range of bioactive lipids in your biosamples: https://lnkd.in/gvGNBy6S

We're thrilled to have been invited to participate in the #AAPS #PharmSci360 Symposium on leveraging #multiomics and #AI in drug discovery and development processes. Join us in Salt Lake City on October 21st for our podium presentation to hear how next-generation, high throughput #massspectrometry is enabling large-scale multi-omics interrogation, and how AI/ML tools are being applied to these complex datasets to derive actionable insights that inform development decisions. 📅 Add the event to your agenda: https://cdmcd.co/wjp7RZ 💬 Pre-schedule a time to meet with the Sapient team during PharmSci 360: https://lnkd.in/g_JU9nW9 American Association of Pharmaceutical Scientists (AAPS) | @aapscomms

Discovery #metabolomics and #lipidomics methods are now able to assay thousands of small molecules in single sample, greatly expanding #biomarker discovery potential but also increasing the likelihood of finding important but unknown metabolites and lipids. Metabolite identification is central towards understanding the biological role of these molecules of interest and to effectively map their involvement in disease processes. We explore approaches to address the complexities of #metabolite and #lipid profiling and to maximize Tier 1 identification of small molecule biomarkers. https://lnkd.in/d9BCqjpS